Back to News

Latigo Biotherapeutics prices IPO at $18 per share

Unable to extract any news content from the provided article text (only '403' received), so no financial developments, figures, or market implications can be determined.

Analysis

Unable to extract any news content from the provided article text (only '403' received), so no financial developments, figures, or market implications can be determined.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Demo

Market Sentiment

Overall Sentiment

neutral

Sentiment Score

0.00

More News